 |
市場調查報告書
商品編碼
1890982
藥物再利用市場按方法、藥物類型、治療領域、給藥途徑、最終用戶和地區分類Drug Repurposing Market, By Approach, By Drug Type, By Therapeutic Area, By Route of Administration, By End User, By Geography |
||||||
預計到 2025 年，藥物再利用市場價值將達到 351.4 億美元，到 2032 年將達到 468.7 億美元，2025 年至 2032 年的複合年成長率為 4.2%。
| 報告內容 | 報告詳情 | ||
|---|---|---|---|
| 基準年： | 2024 | 2025年市場規模： | 351.4億美元 |
| 歷史數據時期： | 2020-2024 | 預測期： | 2025-2032 |
| 預測期間（2025-2032年）： | 4.20% | 2032 年的預測值： | 468.7億美元 |
全球藥物再利用市場代表了一種創新的藥物開發方法，專注於為已已通過核准的藥物尋找新的治療用途，從而顯著縮短傳統藥物開發的時間和相關成本。
藥物再利用（也稱為藥物重定位或治療用途再利用）利用現有藥物已確立的安全性和藥理特性，來滿足不同疾病領域尚未滿足的醫療需求。近年來，這項創新策略發展迅速，尤其是在Sildenafil（最初用於治療高血壓，後來用於治療勃起功能障礙）等成功案例之後，以及近期現有抗病毒藥物迅速應用於新冠肺炎治療之後。
該市場由先進的計算方法、人工智慧和複雜的篩檢技術所驅動，涵蓋腫瘤學、神經系統疾病、感染疾病、心血管疾病和罕見疾病等各種治療領域。
慢性病的增加、醫療保健成本的不斷攀升以及對快速藥物開發解決方案的迫切需求，使得藥物再利用成為現代製藥策略的關鍵要素，為全球製藥公司在降低開發風險、縮短監管流程和提高投資回報率方面帶來了顯著的益處。
市場動態
全球藥物再利用市場主要受以下幾個強大因素驅動，這些因素正在改變製藥業的結構並加速市場成長：傳統藥物開發成本不斷增加且開發週期長（超過 26 億美元，10-15 年），這促使製藥公司採用藥物再利用策略，該策略可將開發成本降低高達 60%，並將開發時間縮短至 3-12 年。
慢性病的增加、全球人口老化以及治療罕見疾病和新出現的健康威脅的迫切性，都對創新治療方案產生了巨大的需求。
然而，該市場面臨許多限制因素，例如複雜的智慧財產權問題、藥物再利用核准管道的監管不確定性，以及學名藥生產商缺乏投資藥物再利用研發的經濟獎勵。此外，各地區缺乏統一的法規結構、新適應症使用可能帶來的安全隱患，以及來自生物相似藥和學名藥的競爭，都對市場成長構成重大挑戰。
儘管存在這些限制，但市場仍存在巨大的機遇，這得益於政府對再利用舉措的支持和資金不斷增加、製藥公司與學術機構之間的夥伴關係日益密切、精準醫療和個性化治療方法的應用不斷擴展，以及人工智慧驅動的藥物發現平台的日益普及。
本次調查的主要特點
- 本報告對全球藥物再利用市場進行了詳細分析，並以 2024 年為基準年，給出了預測期（2025-2032 年）的市場規模（十億美元）和復合年成長率（%）。
- 它還重點介紹了各個細分市場的潛在商機，並解釋了該市場具有吸引力的投資提案矩陣。
- 該研究還提供了有關市場促進因素、限制因素、機會、新產品發布或核准、市場趨勢、區域展望以及主要參與企業。
- 該報告根據以下參數對全球藥物再利用市場的主要參與企業進行了分析：公司概況、產品系列、主要亮點、財務表現和策略。
- 本報告的研究結果將使負責人和企業經營團隊能夠就未來的產品發布、類型升級、市場擴張和行銷策略做出明智的決策。
- 這份全球藥物再利用市場報告針對該行業的各個相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
- 透過分析全球藥物再利用市場的各種策略矩陣，可以促進相關人員的決策。
目錄
第1章 研究目標與前提條件
- 調查目的
- 先決條件
- 簡稱
第2章 市場範圍
- 報告概述
- 市場定義和範圍
- 執行摘要
第3章：市場動態、監理及趨勢分析
- 市場動態
- 促進要素
- 抑制因素
- 機會
- 影響分析
- 法規環境
- 產品上市及核准
- PEST分析
- 波特分析
- 併購趨勢
- 產業趨勢
4. 2020-2032年全球藥物再利用市場（依方法分類）
- 以疾病為中心
- 以目標為中心
- 以藥物為中心
5. 2020-2032年全球藥物再利用市場（依藥物類型分類）
- 低分子化合物
- 生技藥品
6. 2020-2032年全球藥物再利用市場（依治療領域分類）
- 腫瘤學
- 神經病學和中樞神經系統疾病
- 感染疾病
- 心血管疾病
- 代謝性疾病
- 其他
7. 2020-2032年全球藥物再利用市場（依給藥途徑分類）
- 口服
- 靜脈注射
- 其他頻道
8. 2020-2032年全球藥物再利用市場（依最終用戶分類）
- 製藥和生物技術公司
- 受託研究機構（CRO）
- 醫院和診所
- 其他
9. 2020-2032年全球藥物再利用市場（按地區分類）
- 北美洲
- 美國
- 加拿大
- 拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
- 歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲
- 亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 亞太其他地區
- 中東
- GCC
- 以色列
- 其他中東國家
- 非洲
- 南非
- 北非
- 中非
第10章 競爭格局
- Pfizer Inc.
- Novartis AG
- Bristol Myers Squibb Company
- Johnson and Johnson
- AstraZeneca PLC
- Eli Lilly and Company
- Sanofi SA
- GlaxoSmithKline PLC
- Amgen Inc.
- Recursion Pharmaceuticals Inc.
- Melior Discovery Inc.
- Vertex Pharmaceuticals Incorporated
- Ginkgo Bioworks, Inc.
- Paradigm Biopharmaceuticals Ltd
- Teva Pharmaceutical Industries Ltd.
第11章 分析師建議
- 機會
- 一致的機會地圖
第12章 參考文獻與調查方法
- 參考
- 調查方法
- 關於出版商
Drug Repurposing Market is estimated to be valued at USD 35.14 Bn in 2025 and is expected to reach USD 46.87 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.2% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 35.14 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 4.20% | 2032 Value Projection: | USD 46.87 Bn |
The global drug repurposing market represents a revolutionary approach in pharmaceutical development that focuses on identifying new therapeutic applications for existing approved drugs, significantly reducing the traditional drug development timeline and associated costs.
Drug repurposing, also known as drug repositioning or therapeutic switching, leverages the established safety profiles and pharmacological properties of existing medications to address unmet medical needs across various disease areas. This innovative strategy has gained substantial momentum in recent years, particularly following successful repurposing examples such as sildenafil (originally for hypertension, later for erectile dysfunction), and more recently, the rapid deployment of existing antivirals for COVID-19 treatment.
The market encompasses various therapeutic areas including oncology, neurological disorders, infectious diseases, cardiovascular conditions, and rare diseases, driven by advanced computational methods, artificial intelligence, and sophisticated screening technologies.
The growing prevalence of chronic diseases, increasing healthcare costs, and the urgent need for faster drug development solutions have positioned drug repurposing as a critical component of modern pharmaceutical strategies, offering significant advantages in terms of reduced development risks, shortened regulatory pathways, and improved return on investment for pharmaceutical companies worldwide.
Market Dynamics
The global drug repurposing market is primarily driven by several compelling factors that are reshaping the pharmaceutical landscape and accelerating market growth. The escalating costs and extended timelines associated with traditional drug development, which can exceed $2.6 billion and span 10-15 years, are compelling pharmaceutical companies to adopt drug repurposing strategies that can reduce development costs by up to 60% and shorten timelines to 3-12 years.
The increasing prevalence of chronic diseases, aging global population, and the urgent need for treatments for rare diseases and emerging health threats are creating substantial demand for innovative therapeutic solutions.
However, the market faces significant restraints including complex intellectual property challenges, regulatory uncertainties regarding approval pathways for repurposed drugs, and limited financial incentives for generic drug manufacturers to invest in repurposing research. Additionally, the lack of standardized regulatory frameworks across different regions, potential safety concerns when drugs are used for new indications, and competition from biosimilars and generic alternatives pose considerable challenges to market growth.
Despite these constraints, the market presents substantial opportunities driven by increasing government support and funding for repurposing initiatives, growing partnerships between pharmaceutical companies and academic institutions, expanding applications in precision medicine and personalized therapy approaches, and the rising adoption of AI-driven drug discovery platforms.
Key Features of the Study
- This report provides in-depth analysis of the global drug repurposing market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global drug repurposing market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as part of this study include Pfizer Inc., Novartis AG, Bristol-Myers Squibb Company, Johnson & Johnson, AstraZeneca PLC, Eli Lilly and Company, Sanofi S.A., GlaxoSmithKline PLC, Amgen Inc., Recursion Pharmaceuticals Inc., Melior Discovery Inc., Vertex Pharmaceuticals Incorporated, Ginkgo Bioworks Inc., Paradigm Biopharmaceuticals Ltd, and Teva Pharmaceutical Industries Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global drug repurposing market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global drug repurposing market
Market Segmentation
- Approach Insights (Revenue, USD Bn, 2020 - 2032)
- Disease centric
- Target centric
- Drug centric
- Drug Type Insights (Revenue, USD Bn, 2020 - 2032)
- Small molecules
- Biologics
- Therapeutic Area Insights (Revenue, USD Bn, 2020 - 2032)
- Oncology
- Neurology and CNS disorders
- Infectious diseases
- Cardiovascular diseases
- Metabolic disorders
- Other therapeutic areas
- Route Of Administration Insights (Revenue, USD Bn, 2020 - 2032)
- Oral
- Intravenous (IV)
- Other routes
- End User Insights (Revenue, USD Bn, 2020 - 2032)
- Pharmaceutical and biotechnology companies
- Contract research organizations (CROs)
- Hospitals and Clinics
- Others
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- Pfizer Inc.
- Novartis AG
- Bristol Myers Squibb Company
- Johnson and Johnson
- AstraZeneca PLC
- Eli Lilly and Company
- Sanofi S.A.
- GlaxoSmithKline PLC
- Amgen Inc.
- Recursion Pharmaceuticals Inc.
- Melior Discovery Inc.
- Vertex Pharmaceuticals Incorporated
- Ginkgo Bioworks, Inc.
- Paradigm Biopharmaceuticals Ltd
- Teva Pharmaceutical Industries Ltd.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Drug Repurposing Market, By Approach
- Global Drug Repurposing Market, By Drug Type
- Global Drug Repurposing Market, By Therapeutic Area
- Global Drug Repurposing Market, By Route of Administration
- Global Drug Repurposing Market, By End User
- Global Drug Repurposing Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Driver
- Restraint
- Opportunity
- Impact Analysis
- Key Developments
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
- Industry Trends
4. Global Drug Repurposing Market, By Approach, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Disease centric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Target centric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Drug centric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Drug Repurposing Market, By Drug Type, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Small molecules
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Biologics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Drug Repurposing Market, By Therapeutic Area, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oncology
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Neurology and CNS disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Infectious diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Cardiovascular diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Metabolic disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other therapeutic areas
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Drug Repurposing Market, By Route of Administration, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Oral
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Intravenous (IV)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other routes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
8. Global Drug Repurposing Market, By End User, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pharmaceutical and biotechnology companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Contract research organizations (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
9. Global Drug Repurposing Market, By Region, 2020 - 2032, Value (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Approach, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Approach, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Approach, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Approach, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Approach, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Approach, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Drug Type, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Therapeutic Area, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By End User, 2020 - 2032, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
- South Africa
- North Africa
- Central Africa
10. Competitive Landscape
- Pfizer Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Bristol Myers Squibb Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Johnson and Johnson
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- AstraZeneca PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Eli Lilly and Company
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Sanofi S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- GlaxoSmithKline PLC
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Amgen Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Recursion Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Melior Discovery Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Vertex Pharmaceuticals Incorporated
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Ginkgo Bioworks, Inc.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Paradigm Biopharmaceuticals Ltd
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Teva Pharmaceutical Industries Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
11. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
12. References and Research Methodology
- References
- Research Methodology
- About us
